Eugia Faces USFDA Wrath For Serious Production Lapses

The US Food and Drug Administration (FDA) has issued a warning to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, over manufacturing issues at its facility in Telangana. The FDA's letter to Eugia's CEO, Yugandhar Puvvala, highlighted concerns about the company's failure to maintain accurate production and process simulation data. The regulator noted deficiencies in laboratory records, which lacked complete data from necessary tests to meet established specifications and standards.

The FDA conducted an inspection at the plant in Patancheru, Sangareddy, Hyderabad, from January 22 to February 2, 2024. Findings included inaccuracies in production and process simulation data, falsified environmental monitoring records for multiple aseptic filling lines, and incomplete batch production and control records. The inspection also revealed issues with the documentation of equipment cleaning, disinfection, and sterilization procedures.

In response, an Aurobindo Pharma spokesperson assured that there is no immediate impact on US market supplies and emphasized the company's commitment to improving compliance and working closely with the FDA. The FDA criticized Eugia for not implementing adequate written procedures to prevent microbiological contamination in sterile drug products and for failing to validate aseptic and sterilization processes. The warning letter, which highlights significant violations of Current Good Manufacturing Practice (CGMP) regulations, demands a detailed corrective action plan addressing data integrity issues and evidence of adequate measures to resolve the identified problems.

The FDA has warned that approval of new drug applications or supplements listing Eugia as a manufacturer may be withheld until the issues are resolved. The agency may re-inspect to verify corrective actions and requires a written response within 15 working days detailing the steps taken to address the deviations and prevent their recurrence.

Typically, an FDA warning letter outlines specific violations, such as manufacturing problems, misleading product claims, or incorrect usage directions. It requires the company to correct these issues and provide a plan and timeline for doing so, with follow-up inspections to ensure the adequacy of the corrections.